Compare CCNE & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCNE | GERN |
|---|---|---|
| Founded | 1865 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 736.3M | 753.3M |
| IPO Year | N/A | 1996 |
| Metric | CCNE | GERN |
|---|---|---|
| Price | $27.10 | $1.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $29.00 | $3.00 |
| AVG Volume (30 Days) | 137.9K | ★ 7.8M |
| Earning Date | 01-16-2026 | 02-25-2026 |
| Dividend Yield | ★ 2.66% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.91 | N/A |
| Revenue | ★ $227,923,000.00 | $183,403,000.00 |
| Revenue This Year | $13.84 | $147.42 |
| Revenue Next Year | $27.68 | $37.07 |
| P/E Ratio | $14.19 | ★ N/A |
| Revenue Growth | 5.27 | ★ 522.13 |
| 52 Week Low | $19.32 | $1.04 |
| 52 Week High | $28.04 | $3.12 |
| Indicator | CCNE | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 58.61 | 49.20 |
| Support Level | $25.72 | $1.28 |
| Resistance Level | $26.73 | $1.48 |
| Average True Range (ATR) | 0.56 | 0.08 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 87.50 | 16.92 |
CNB Financial Corp is providing integrated financial solutions, which create value for both consumers and businesses. These solutions encompass deposit accounts, private banking, real estate, commercial, industrial, residential and consumer loans and lines of credit, credit cards, treasury services, online banking, mobile banking, merchant credit card processing, remote deposit and accounts receivable handling. It derives revenue through the operations as a full-service bank engaging in a full range of banking activities and services, including trust and wealth management services, for individual, business, governmental, and institutional customers. The company branch are located in Pennsylvania, Ohio, New York and Virginia.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.